Skip to main content
Premium Trial:

Request an Annual Quote

Argos Soditic Acquires Cisbio Bioassays

NEW YORK (GenomeWeb News) – Private equity group Argos Soditic and management members of Cisbio Bioassays today announced that they have acquired Cisbio Bioassays from IBA for an undisclosed amount.

As a result, Cisbio will operate as an independent company.

Based in Codolet, France, Cisbio provides assays and reagents to researchers in the pharmaceutical, biotechnology, and academic markets, as well as to contract research organizations. Its technology portfolio includes Homogeneous Time Resolved Fluorescence. The company has facilities in Bedford, Mass., and Shanghai, and has 200 employees.

Cisbio said that it generates annual revenues of about €35 million ($47.4 million).

The deal will open up opportunities "for strategic growth and will enable [Cisbio] to strengthen its market positions," the firms said, adding that Argos Soditic will help Cisbio implement its strategic plan of innovation, new product launches, and international development.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.